A Study on the Efficacy and Safety of IPyC for HER2+ MBC

A Retrospective Multicenter Cohort Study on the Efficacy and Safety of Inetetamab and Pyrotinib Combined With Chemotherapy for HER2-positive Metastatic Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06990347

Enrollment

301

Registered

2025-05-25

Start date

2020-07-01

Completion date

2025-05-01

Last updated

2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).

Interventions

DRUGInetetamab and Pyrotinib Combined with Chemotherapy

Inetetamab and Pyrotinib Combined with Chemotherapy

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* patients who underwent a biopsy of the metastatic site and were confirmed as having MBC * patients who received inetetamab + pyrotinib + chemotherapy as metastasis therapy.

Exclusion criteria

* male patients or individuals with prior malignancy * patients with prior or current enrollment in interventional clinical trials for MBC * patients who received less than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib) * patients who were lost to follow-up during the therapeutic process

Design outcomes

Primary

Measure	Time frame
progression-free survival (PFS)	2 years

Secondary

Measure	Time frame
objective response rate (ORR)	2 years
clinical benefit rate (CBR)	2 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026